Tapping the Potential of Psychedelics to Treat Psychiatric Conditions

Psychedelics have long been viewed as having potential to treat a range of mental health disorders including depression, addiction, PTSD, and ADHD. Government policies, though, have long impeded studies of their benefits. Mind Medicine is developing a pipeline of therapies based on psychedelics in the hopes of developing needed medicines for psychiatric conditions. Its lead experimental therapy is an ibogaine-derived molecule for the treatment of opioid addiction. We spoke to Steve Hurst, founder and CEO of MindMed, about the potential for psychedelic-based medicines, what’s known about them to date, and the challenges of working with these substances.